BMO Capital Starts Protagonist Therapeutics (PTGX) at Outperform

BMO Capital analyst George Farmer initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Outperform rating and a price target of $17.00.

The analyst commented, "Recent stock pullback offers an attractive entry point, in our view, based on the potential of PTGX's novel peptide chemistry platform. We believe derived drug candidates have demonstrated impressive proof-of-concept when delivered both as IV and oral means of administration. Positive outcomes of upcoming catalysts this year could drive shares close to our $17 target price, in our view."

For an analyst ratings summary and ratings history on Protagonist Therapeutics click here. For more ratings news on Protagonist Therapeutics click here.

Shares of Protagonist Therapeutics closed at $7.16 yesterday.

You May Also Be Interested In

• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell
• Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation